MALVERN, PA — Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, recently announced that the Compensation Committee of Baudax Bio’s Board of Directors approved an inducement grant of stock options to purchase an aggregate of 7,500 shares of Baudax Bio’s common stock and restricted stock units covering 2,000 shares of Baudax Bio’s common stock in connection with one newly-hired employee with a grant date of March 31, 2021.
The equity award was granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of the individual’s employment compensation and was granted as an inducement material to his acceptance of employment with Baudax Bio.
The options have an exercise price equal to $1.29 per share, the closing price of Baudax Bio’s common stock as reported by Nasdaq on March 31, 2021. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying the stock option vesting on the one-year anniversary of the grant date and the remaining shares vesting monthly over 36 months thereafter. The restricted stock units vest annually over four years. The equity awards are subject to the employee’s continued service with Baudax Bio through the applicable vesting dates.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.